Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

LD50 oral, rat: > 2000 mg/kg bw

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
according to guideline
OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
according to guideline
EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
GLP compliance:
yes (incl. QA statement)
Test type:
fixed dose procedure
Limit test:
Details on test animals or test system and environmental conditions:
- Source:
Janvier Labs SAS, Le Genest St. Isle, 53941 Saint Berthevin Cedex, France
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation:
8 - 12 weeks
- Weight at study initiation:
204 - 246 g
- Fasting period before study:
- Housing:
groups of one to five rats
- Historical data:
- Diet (e.g. ad libitum):
ad libitum
- Water (e.g. ad libitum):
ad libitum
- Acclimation period:
at least 5 days prior to start of dosing

- Temperature (°C):
22 +/- 2°C
- Humidity (%):
- Air changes (per hr): at least 8 per hour
- Photoperiod (hrs dark / hrs light):

IN-LIFE DATES: From: 2020-07-20 To: 2020-08-12
Route of administration:
oral: gavage
Details on oral exposure:
- Concentration in vehicle: 30 and 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw
- Justification for choice of vehicle: stability in vehicle given

CLASS METHOD (if applicable)
- In the absence of data regarding the toxicity of the test item 300 mg/kg was chosen as the initial starting dose, since a severe toxicity which may necessitate humane euthanasia was not expected at this dose level.
300 and 2000 mg/kg bw
No. of animals per sex per dose:
1 female for the pre-test with 300 mg/kg bw and 2000 mg/kg bw each
4 females for the main study with 2000 mg/kg bw
Control animals:
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations and inspections for morbidity / mortality were performed at least three times within the first six hours after application (i.e., 30 minutes and 1 hour, 2 hours and 4 hours after dosing), thereafter at least once daily for 14 days. Body weights were recorded on Day 0 (prior to dosing), Day 7, and 14.
- Necropsy of survivors performed: yes
not needed
Preliminary study:
In the sighting test with one female and a single dose of 2000 mg/kg bw
Dose descriptor:
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
One female (animal number 2) had to be humanely euthanised on day 1 after application due to deterioration of clinical signs.
Clinical signs:
other: Clinical signs included secretion of Harderian glands, fur stained by the test item, staining around the mouth, blue to black staining of the skin, staining of the urine and faeces. The euthanized animal showed the following additional symptoms: hunched p
Gross pathology:
Three animals showed dark kidneys, possibly due to test item residuals in the parenchyma.
For animal number 2 discoulouring of the following organs to blue was noted: fur, skin, orifices, tongue, pharynx, eyes, mucosa, small and large intestine, peritoneum, kidneys, and caecum. The skin of the urinary bladder was discoloured as well but the content was clear.
Additionally, fluffed-up cheeks and a thickened right masseter muscle, a filled stomach and a moniliform content of the small intestine and black content of the caecum was observed.
Interpretation of results:
GHS criteria not met
Executive summary:

The registered substance was tested at a starting dose of 300 mg/kg bw and at 2000 mg/kg bw in the main study of an acute oral toxicity study in female Wistar rats following OECD TG 420. One animal of the main test treated with 2000 mg/kg body weight was euthanized on day 1 after application due to deterioration of clinical signs that were, if compared to the symptoms observed in the four other animals dosed with 2000 mg/kg b.w., unexpectedly severe. Therefore, it is possible that these individual symptoms were incidental. Clinical signs in the other 4 animals included secretion of Harderian glands, and staining by the couloured test item of fur, mouth, skin, urine and faeces. The acute median lethal oral dose (LD50) was demonstrated to be > 2000 mg/kg bw.

Endpoint conclusion
Dose descriptor:
> 2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
acute toxicity: dermal
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
the study does not need to be conducted because the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and, in the absence of an in vivo study by the oral route, no systemic effects after dermal exposure are predicted on the basis of non-testing approaches (e.g. read across, QSAR studies)
Endpoint conclusion
Quality of whole database:
No acute dermal toxicity expected.

Additional information

Justification for classification or non-classification

No classification for acute oral toxicity is warranted (LD50 oral, rat > 2000 mg/kg bw). Based on this result no acute dermal toxicity is expected.